Table 2.
Main Outcome Measures of the Trial
| Parameters | Eplerenone Baseline | Eplerenone 4 Weeks | Placebo Baseline | Placebo 4 Weeks | P Valuea |
|---|---|---|---|---|---|
| Endothelial function | |||||
| FMD, % | 4.6 ± 2.4 | 4.7 ± 2.0 | 5.1 ± 2.2 | 4.9 ± 2.1 | 0.77 |
| GTN, % | 12.4 ± 4.9 | 12.6 ± 5.7 | 13.8 ± 5.7 | 12.8 ± 12.8 | 0.90 |
| Hemodynamic measures | |||||
| 24‐hour SBP, mm Hg | 128.1 ± 14.0 | 126.9 ± 17.3 | 124.1 ± 11.5 | 123.3 ± 9.7 | 0.41 |
| 24‐hour DBP, mm Hg | 75.3 ± 9.6 | 73.3 ± 12.9 | 72.5 ± 7.6 | 72.0 ± 7.5 | 0.69 |
| 24‐hour heart rate, bpm | 65.5 ± 9.7 | 66.8 ± 9.8 | 65.2 ± 7.6 | 66.3 ± 8.4 | 0.86 |
| Office SBP, mm Hg | 129.9 ± 9.6 | 126.2 ± 11.8 | 133.0 ± 13.5 | 127.5 ± 11.7 | 0.72 |
| Office DBP, mm Hg | 79.5 ± 8.5 | 75.6 ± 9.5 | 79.0 ± 8.7 | 77.1 ± 6.2 | 0.54 |
| Heart rate, bpm | 58.8 ± 9.3 | 58.3 ± 10.2 | 59.9 ± 8.2 | 60.4 ± 7.9 | 0.46 |
| Laboratory parameters | |||||
| Na, mmol/L | 139.8 ± 2.4 | 139.4 ± 1.8 | 140.0 ± 1.7 | 140.0 ± 1.6 | 0.22 |
| K, mmol/L | 4.0 ± 0.3 | 4.0 ± 0.2 | 3.9 ± 0.3 | 3.9 ± 0.2 | 0.05 |
| Cr, µmol/L | 83.9 ± 11.0 | 92.1 ± 18.7 | 83.9 ± 11.0 | 84.5 ± 12.3 | 0.13 |
| Glucose, mmol/L | 5.5 ± 0.7 | 5.5 ± 0.8 | 5.3 ± 0.5 | 5.3 ± 0.9 | 0.53 |
| proBNP, ng/L | 142 (65.3–254.8) | 119 (56–249.8) | 129 (84.5–217.5) | 110 (52.5–202.5) | 0.41 |
| hsCRP, mg/L | 1.0 (0.4–3.3) | 0.85 (0.43–2.4) | 1.0 (0.6–1.2) | 0.7 (0.6–1.5) | 0.95 |
| EPC, % | 0.7 (0.5–1.7) | 1.3 (1–4.5) | 0.7 (0.4–1.3) | 1.7 (0.8–2.4) | 0.62 |
| Platelet adhesion, % | 3.9 ± 1.9 | 3.9 ± 1.6 | 3.9 ± 1.2 | 4.1 ± 2.3 | 0.83 |
Abbreviations: Cr, creatinine; DBP, diastolic blood pressure; EPC, endothelial progenitor cells; FMD, flow‐mediated vasodilatation; GTN, glycerol trinitrate–mediated vasodilatation; hsCRP, high‐sensitivity C‐reactive protein; IQR, interquartile range; K, potassium; Na, sodium; proBNP, pro‐brain natriuretic peptide; SBP, systolic blood pressure; SD, standard deviation.
Values are presented as mean ± SD or median (IQR).
a
Difference between intervention and control at 4 weeks.